Panbela Therapeutics, Inc. (PBLA) |
|
0.51 0.022 (4.51%)
|
03-24 16:00 |
|
Open: |
0.481 |
Pre. Close: |
0.488 |
|
High:
|
0.53 |
Low:
|
0.48 |
|
Volume:
|
488,725 |
Market Cap:
|
7(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:28:41 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.25  One year: 1.72 |
| Support: |
Support1: 0.4 Support2: 0.34 |
| Resistance: |
Resistance1: 1.07 Resistance2: 1.48 |
| Pivot: |
0.63 |
| Moving Average: |
MA(5): 0.51 MA(20): 0.74
MA(100): 2.88 MA(250): 26.43 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 17.3 %D(3): 15.9 |
| RSI: |
RSI(14): 26.5 |
| 52-week: |
High: 87.59 Low: 0.4 |
| Average Vol(K): |
3-Month: 1,905 (K) 10-Days: 943 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PBLA ] has closed above bottom band by 22.2%. Bollinger Bands are 78.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 124 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.53 - 0.53 |
0.53 - 0.54 |
|
Low:
|
0.47 - 0.48 |
0.48 - 0.48 |
|
Close:
|
0.51 - 0.51 |
0.51 - 0.51 |
|
Company Description |
|
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. |
Headline News |
Mon, 20 Mar 2023
Breakeven On The Horizon For Panbela Therapeutics, Inc. (NASDAQ:PBLA) - Simply Wall St
Sat, 18 Mar 2023
Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2022 Earnings Call Transcript - Yahoo Finance
Thu, 16 Mar 2023
Panbela Provides Business Update and Reports Q4 and FY 2022 ... - GlobeNewswire
Thu, 16 Mar 2023
Panbela Therapeutics Reports Q4 2022 Financial Results - Best Stocks
Wed, 08 Mar 2023
Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023 - Yahoo Finance
Thu, 02 Mar 2023
Should You Sell Panbela Therapeutics Inc (PBLA) Stock Thursday Morning? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
1 (M) |
|
% Held by Insiders
|
741500 (%) |
|
% Held by Institutions
|
6.5 (%) |
|
Shares Short
|
20 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-92.1 |
|
Return on Equity (ttm)
|
-1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
295.62 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-0.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0.52 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
417690 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-11-07 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
